Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib in 1st-Line Renal Cell Carcinoma
NCT01791387Phase 2Unknown
- Sponsor
- Auckland District Health Board
- Start
- Mar 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dovitinib in clear cell renal cell carcinoma (ccRCC), sponsored by Auckland District Health Board. Status: unknown.
02
Drugs
dovitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT01791387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01791387.